NEW YORK (GenomeWeb News) – Australian molecular diagnostics company Immunexpress Group today announced a A$982,707 (US$888,101) grant that it will use to further develop its PCR-based test for sepsis.

The grant comes from Commercialisation Australia, an Australian government initiative, and will go toward Immunexpress' A$2.2 million project to bring its whole blood qRT-PCR test called SeptiCyte Plus to market. The assay is for diagnosing sepsis "within a clinically relevant timeframe," the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.